IS2877B - Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð - Google Patents

Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð

Info

Publication number
IS2877B
IS2877B IS7889A IS7889A IS2877B IS 2877 B IS2877 B IS 2877B IS 7889 A IS7889 A IS 7889A IS 7889 A IS7889 A IS 7889A IS 2877 B IS2877 B IS 2877B
Authority
IS
Iceland
Prior art keywords
aspirin
pravastatin
layer containing
tablet containing
containing pravastatin
Prior art date
Application number
IS7889A
Other languages
English (en)
Other versions
IS7889A (is
Inventor
Loutfy Benkerrour
Olivier Galley
Francoise Quinet
Peter Timmins
Admassu Abebe
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32505946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2877(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IS7889A publication Critical patent/IS7889A/is
Publication of IS2877B publication Critical patent/IS2877B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS7889A 2002-12-11 2005-06-10 Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð IS2877B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/316,424 US20040115265A1 (en) 2002-12-11 2002-12-11 Multilayered tablet containing pravastatin and aspirin and method
PCT/US2003/038774 WO2004052289A2 (en) 2002-12-11 2003-12-03 Multilayered tablet containing pravastatin and aspirin

Publications (2)

Publication Number Publication Date
IS7889A IS7889A (is) 2005-06-10
IS2877B true IS2877B (is) 2014-04-15

Family

ID=32505946

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7889A IS2877B (is) 2002-12-11 2005-06-10 Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð

Country Status (17)

Country Link
US (1) US20040115265A1 (is)
EP (1) EP1581194B1 (is)
JP (1) JP2006511520A (is)
AT (1) ATE401061T1 (is)
AU (1) AU2003297689A1 (is)
CY (1) CY1108414T1 (is)
DE (1) DE60322264D1 (is)
DK (1) DK1581194T3 (is)
ES (1) ES2308040T3 (is)
IS (1) IS2877B (is)
MY (1) MY140947A (is)
NO (1) NO338696B1 (is)
PL (1) PL206190B1 (is)
PT (1) PT1581194E (is)
SI (1) SI1581194T1 (is)
TW (1) TWI361700B (is)
WO (1) WO2004052289A2 (is)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096201A1 (en) 2003-04-29 2004-11-11 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
JP2008526771A (ja) * 2004-12-30 2008-07-24 ジェンザイム コーポレーション 高リン酸血症のための亜鉛含有処置
US20060251722A1 (en) * 2005-05-03 2006-11-09 Novavax, Inc. Multi-component vitamin and mineral supplement for the optimal absorption of components
WO2007027566A2 (en) * 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
EP2135603B1 (en) 2005-11-22 2013-01-02 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007072060A2 (en) * 2005-12-23 2007-06-28 Cipla Limited Particles comprising a core containing a hmg-coa reductase inhibitor and coated with a film
WO2007073702A2 (es) 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
TWI609702B (zh) * 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
KR20180066272A (ko) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
CA2681158C (en) 2007-03-13 2018-09-18 Nutrition 21, Inc. Methods and compositions for the sustained release of chromium
WO2009002867A2 (en) * 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
US8481083B2 (en) 2007-10-12 2013-07-09 Ferring International Center S.A. Granular compositions of magnesium oxide and citric acid and uses thereof
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
RU2616496C2 (ru) 2010-01-11 2017-04-17 Ориксиджен Терапьютикс, Инк. Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
TR201005325A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Atorvastatin ve aspirin içeren farmasötik formülasyonlar
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
US8718837B2 (en) * 2011-01-28 2014-05-06 Intouch Technologies Interfacing with a mobile telepresence robot
WO2013184837A1 (en) 2012-06-06 2013-12-12 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
EP2810644A1 (en) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Oral formulation for the treatment of cardiovascular diseases
US11865121B2 (en) 2016-02-11 2024-01-09 Nutrition21, LLC Chromium containing compositions for improving health and fitness
JP7109748B2 (ja) * 2018-12-11 2022-08-01 日本ジェネリック株式会社 アジルサルタンとアムロジピンベシル酸塩含有固形製剤及び固形製剤の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
JP3172749B2 (ja) * 1992-02-17 2001-06-04 ライオン株式会社 イブプロフェン含有製剤
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
IT1264517B1 (it) * 1993-05-31 1996-09-24 Ekita Investments Nv Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
CA2320900C (en) * 1998-03-19 2009-10-27 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
MY140947A (en) 2010-02-12
WO2004052289A2 (en) 2004-06-24
JP2006511520A (ja) 2006-04-06
IS7889A (is) 2005-06-10
EP1581194B1 (en) 2008-07-16
PL377265A1 (pl) 2006-01-23
WO2004052289A3 (en) 2005-03-24
US20040115265A1 (en) 2004-06-17
ES2308040T3 (es) 2008-12-01
AU2003297689A1 (en) 2004-06-30
CY1108414T1 (el) 2014-02-12
TW200505432A (en) 2005-02-16
NO20052734L (no) 2005-07-07
SI1581194T1 (sl) 2008-12-31
ATE401061T1 (de) 2008-08-15
DE60322264D1 (de) 2008-08-28
DK1581194T3 (da) 2008-10-20
NO338696B1 (no) 2016-10-03
NO20052734D0 (no) 2005-06-07
TWI361700B (en) 2012-04-11
PT1581194E (pt) 2008-09-24
AU2003297689A8 (en) 2004-06-30
EP1581194A4 (en) 2006-03-15
EP1581194A2 (en) 2005-10-05
PL206190B1 (pl) 2010-07-30

Similar Documents

Publication Publication Date Title
IS7889A (is) Lagskipt tafla, sem inniheldur pravastatín og aspirín, og aðferð
AU2003251642A1 (en) Laser markable carrier unit
PE20000349A1 (es) Composicion farmaceutica que contiene una combinacion de una estatina y aspirina
AU2003295370A1 (en) Gas layer formation materials
MXPA02012638A (es) Peliculas de barrera de alta humedad.
ATE279915T1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
AU2002219972A1 (en) Microelectronic package having bumpless laminated interconnection layer
DE50007387D1 (de) Strahlungshärtbare verbundschichtplatte oder -folie
AU2003236831A1 (en) Materials containing multiple layers of vesicles
PE20120542A1 (es) Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
MX2007010224A (es) Uso de un catalizador de varias capas para producir anhidrido ftalico.
BR9911254A (pt) Estrutura de camadas múltiplas
AU2002328410A1 (en) Adhesive for gas barrier laminates and laminated films
HUP0001948A2 (hu) Szimmetrikus, többrétegű rétegszerkezet, valamint eljárás szimmetrikus, többrétegű rétegszerkezet előállítására
AU2003234610A1 (en) Higher layer bonding of multiple access lines for carrier grade access
ATE374425T1 (de) Zweilagige schutzschicht
DE50006328D1 (de) Transparente biaxial orientierte polyolefinfolie
AU2002356226A1 (en) Multilayer sealing materials or peelable seals
WO2007147125A3 (en) Tetracycline package formulations
AU2003285237A8 (en) Barrier layer for thick film dielectric electroluminescent displays
TH69755A (th) ยาเม็ดชนิดหลายชั้นซึ่งมีพราวาสเตติน และแอสไพริน และวิธี
WO2005081651A3 (en) Housebuilding, wall element and method related thereto
PL371753A1 (pl) Sposób wytwarzania domieszkowanych warstw epitaksjalnych InxAlyGa1-x-yN, domieszkowana warstwa epitaksjalna InxAlyGa1-x-yN i półprzewodnikowa struktura wielowarstwowa zawierająca warstwę epitaksjalną InxAlyGa1-x-yN, dla której 1 ˛ x > 0.001 a 0.999 ˛ y > 0
AU2003244318A1 (en) Transparent laminated film having barrier property and method for production thereof
AU2003266636A1 (en) Laminate comprising silver layer and, formed thereon, layer for stabilizing the same